Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)A ABATACEPT (GENETICAL RECOMBINATION) (250MG/VIAL) 433 VIALS B DASATIN IB HYDRATE (50MG 30TABLETS/CASE) 104 CASES C AMBRISENTAN (2.5MG 60TABL ETS/CASE) 194 CASES D DOLUTEGRAVIR SODIUM, ABACAVIR SULFATE, LAMIVUDIN E (30TABLETS/VIAL) 108 VIALS E TEMOZOLOMIDE (100MG 5CAPSULES/CASE) 917 CASES F SUGA...

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Feb 13, 2018
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Niigata
Classification
0004 Medical & Pharmaceutical Products
Summay of notice 5 Summary
(1) Official in charge ofdisbursement of the procuring
entity : Sugata Takahashi,President, National University
Corporation Niigata University
(2) Classification of the products
to be procured : 4
(3) Nature and quantity of theproducts to be purchased :
A Abatacept (GeneticalRecombination) (250mg/vial) 433
vials
B Dasatinib Hydrate (50mg30tablets/case) 104 cases
C Ambrisentan (2.5mg60tablets/case) 194 cases
D Dolutegravir Sodium, AbacavirSulfate, Lamivudine
(30tablets/vial) 108 vials
E Temozolomide (100mg5capsules/case) 917 cases
F Sugammadex Sodium (200mg 2ml10vials/case) 262 cases
G Macitentan (10mg30tablets/case) 107 cases
H Bosentan Hydrate (62.5mg60tablets/case) 93 cases
I Enzalutamide (40mg56capsules/case) 149 cases
J Certolizumab Pegol (GeneticalRecombination) (200mg 1ml/syringe)
336 syringes
K Micafungin Sodium (50mg10vials/case) 407 cases
L Tacrolimus Hydrate (1mg100capsules/case) 293 cases
M Goserelin Acetate(10.8mg/syringe (as goserelin)) 431
syringes
N Osimertinib Mesilate (80mg14tablets/case) 131 cases
O Palivizumab (GeneticalRecombination) (100mg 1ml/vial) 347
vials
P Asfotase Alfa (GeneticalRecombination) (28mg 0.7ml/vial)
362 vials
Q Asfotase Alfa (GeneticalRecombination) (40mg 1ml/vial) 199
vials
R Eculizumab (GeneticalRecombination) (300mg 30ml/vial)
163 vials
S Eribulin Mesilate (1mg2ml/vial) 252 vials
T Adalimumab (GeneticalRecombination) (40mg 0.4ml/syringe)
550 syringes
U Imiglucerase (GeneticalRecombination) (400units/vial) 95
vials
V Agalsidase beta (GeneticalRecombination) (35mg/vial) 78 vials
W Agalsidase beta (GeneticalRecombination) (5mg/vial) 178 vials
X Lenalidomide Hydrate (5mg40capsules/case) 161 cases
Y Everolimus (5mg 30tablets/case)
86 cases
Z Imatinib mesilate (100mg120tablets/case) 116 cases
AANilotinibhydrochlorideHydrate(150
mg 120capsules/case) 48 cases
AB Ranibizumab (GeneticalRecombination) (0.5mg
0.05ml/syringe) 151 syringes
AC Riociguat (1mg100tablets/case) 141 cases
AD Interferon beta-1a (GeneticalRecombination) (30μg 0.5ml/syringe)
741 syringes
AE Axitinib (5mg 10tablets/case)204 cases
AF Linezolid (600mg10tablets/case) 182 cases
AG Bosutinib Hydrate (100mg50tablets/case) 101 cases
AHDexmedetomidineHydrochloride(200
μg 2ml 5vials/case) 709 cases
AI Bexarotene (75mg14capsules/case) 512 cases
AJ Cetuximab (GeneticalRecombination) (100mg 20ml/vial)
1,907 vials
AK Oxaliplatin (100mg 20ml/vial)509 vials
AL Abiraterone Acetate (250mg56tablets/case) 105 cases
AM Golimumab (GeneticalRecombination) (50mg 0.5ml/syringe)
172 syringes
AN Ustekinumab (GeneticalRecombination) (45mg 0.5ml/syringe)
120 syringes
AO Bortezomib (3mg/vial) 281vials
AP Pegfilgrastim (GeneticalRecombination) (3.6mg
0.36ml/syringe) 378 syringes
AQ Aflibercept (GeneticalRecombination) (2mg 0.05ml/vial)
370 vials
AR Nivolumab (100mg 10ml/vial)392 vials
AS Nivolumab (20mg 2ml/vial) 651vials
AT Tazobactam, PiperacillinHydrate (4.5g 10vials/case) 1,591
cases
AU Meropenem Hydrate (500mg10vials/case) 2,000 cases
AV Paclitaxel (100mg/vial) 761vials
AW Palonosetron Hydrochloride(0.75mg 50m l5bags/case) 503 cases
AX Denosumab (GeneticalRecombination) (120mg 1.7ml/vial)
761 vials
AY Tocilizumab (GeneticalRecombination) (200mg 10ml/vial)
1,499 vials
AZ Tocilizumab (GeneticalRecombination) (80mg 4ml/vial)
1,696 vials
BA Tocilizumab (GeneticalRecombination) (162mg 0.9ml/kit)
1,627 kits
BB Bevacizumab (GeneticalRecombination) (100mg 4ml/vial)
1,609 vials
BC Bevacizumab (GeneticalRecombination) (400mg 16ml/vial)
1,416 vials
BD Alectinib Hydrochloride (150mg
28capsules/case) 172 cases
BE Erlotinib Hydrochloride (150mg
14tablets/case) 137 cases
BF Pertuzumab (GeneticalRecombination) (420mg 14ml/vial)
109 vials
BG Trastuzumab (GeneticalRecombination) (150mg/vial (with
solution)) 889 vials
BH Trastuzumab (GeneticalRecombination) (60mg/vial (with
solution)) 885 vials
BI Rituximab (GeneticalRecombination) (500mg 50ml/vial)
204 vials
BJ Elvitegravir, Cobicistat,Emtricitabine, Tenofovir
Alafenamide Fumarate(30tablets/vial) 120 vials
BK Nafamostat Mesilate (50mg10vials/case) 917 cases
BL Ganciclovir (500mg/vial) 1,659
vials
BM Infliximab (GeneticalRecombination) (100mg/vial) 2,585
vials
BN Polyethylene Glycol TreatedHuman Normal Immunoglobulin (10g
200ml/vial) 344 vials
BO Pemetrexed Sodium Hydrate(100mg/vial) 743 vials
BP Pemetrexed Sodium Hydrate(500mg/vial) 265 vials
BQ Ramucirumab (GeneticalRecombination) (500mg 10ml/vial) 62
vials
BR Nintedanib Ethanesulfonate(150mg 28capsules/case) 128 cases
BS Afatinib Maleate (40mg14tablets/case) 156 cases
BT Paclitaxel (30mg 5ml/vial)6,738 vials
BU Azacitidine (100mg/vial) 369vials
BV Etanercept (GeneticalRecombination) (25mg 0.5ml
4syringes/case) 463 cases
BW Glatiramer Acetate (20mg 1ml7syringe/case) 557 cases
BX Panitumumab (GeneticalRecombination) (100mg 5ml/vial) 289
vials
BY Leuprorelin Acetate(11.25mg/syringe) 361 syringes
BZ Freeze-dried PolyethyleneGlycol Treated Human Normal
Immunoglobulin (5g 100ml/vial (with
solution)) 891 vials
(4) Delivery period : From 1 May,2018 through 31 March, 2019
(5) Delivery place : NiigataUniversity Medical and Dental
Hospital
(6) Qualifications forparticipating in the tendering
procedures : Suppliers eligible for
participating in the proposedtender are those who shall :
A not come under Article 4 overthe past one year and Article 3 of
the Regulation concerning theContract for Niigata University
Furthermore, minors, Person underConservatorship or Person under
Assistance that obtained theconsent necessary for concluding a
contract may be applicable undercases of special reasons within the
said clause,
B have the Grade A or Grade Bqualification during fiscal 2018 in
the Kanto・Koshinetsu area in sales
of product for participating intenders by Single qualification for
every ministry and agency,
C prove to have obtained thefirst-class license for selling
drugs in accordance with the Law on
Securing Quality, Efficacy andSafety of Products including
Pharmaceuticals and MedicalDevices,
D prove to have the ability todeliver the products, required by
this notice, on the date and to the
place specified by the President,National University Corporation
Niigata University,
E meet the qualificationrequirements which President,
National University CorporationNiigata University may specify in
accordance with Article 5 of theRegulation,
F not be currently under asuspension of business order as
instructed by President, NationalUniversity Corporation Niigata
University.
(7) Time limit of tender : 17 : 15
6 April, 2018
(8) Contact point for the notice :
Tomohiro Hoshino, ProcurementSection, Niigata University Medical
and Dental Hospital, 754Asahimachidori 1-bancho Chuo-ku
Niigata-shi 951-8520 Japan, TEL025-227-2430